U.S. Stock Market Midday Update

Teva Pharmaceutical Industries rose 10.19%. Based on recent key news:

1. On July 29, Teva Pharmaceutical Industries announced its second-quarter financial report. Despite a decline in generic drug sales, strong growth in innovative products drove overall performance. The company raised its revenue forecast for 2026 to between $16.5 billion and $16.85 billion, resulting in a stock price increase.

2. On July 29, Teva Pharmaceutical Industries announced the acquisition of Emalex Biosciences, which is expected to have a positive impact on long-term growth. This move enhanced market confidence in the company's future development, driving the stock price up.

3. On July 29, Teva Pharmaceutical Industries sought guidance from the U.S. government on the import tariff plan for generic drugs over the next two years, highlighting the company's strategic importance in the U.S. market and further boosting the stock price. The pharmaceutical industry's innovative product growth is significant.

Stocks with High Trading Volume in the Industry

Eli Lilly fell 0.50%, with increased trading volume. Based on recent key news:

1. On July 29, Eli Lilly signed a strategic cooperation memorandum with Tsinghua University to explore the application of large language models in health communication and other fields. This move is seen as an important layout for the company in the biopharmaceutical innovation sector, potentially having a positive impact on long-term development.

2. On July 28, competition in the global GLP-1 weight loss drug market intensified for Eli Lilly. Novo Nordisk's expansion in the Indian market and competition from generic drugs pose challenges to Eli Lilly, affecting its market share.

3. On July 28, Eli Lilly's ranking improved in the 2026 Fortune Global 500 list, with profit margins ranking second. Nevertheless, market concerns about its future profitability may lead to stock price fluctuations. The GLP-1 drug market is highly competitive, with increasing macroeconomic uncertainty.

Johnson & Johnson fell 0.54%, with increased trading volume. Based on recent key news:

1. On July 28, Johnson & Johnson announced a $5.5 billion settlement related to talc powder lawsuits, covering 99.75% of pending cases. This move may end long-term legal disputes, with the stock price rising 1% in pre-market trading. Source: Guandian.com

2. On July 28, Johnson & Johnson reached an agreement with plaintiff lawyers to resolve approximately 69,000 talc powder lawsuits. The agreement requires 95% of plaintiffs' consent and is expected to end a 15-year dispute. Source: TMTPost

3. On July 28, Johnson & Johnson's stock price rose 2% due to the settlement news, potentially eliminating legal risk exposure. Source: Zhitong Finance. The pharmaceutical industry faces legal risks and technological innovation challenges.

Pfizer fell 0.53%, with increased trading volume. Based on recent key news:

1. On July 27, Pfizer's Chief Financial Officer, Amit Agarwal, resigned, increasing uncertainty in the company's management and putting pressure on the stock price.

2. On July 28, Pfizer suspended the sale of a popular menopausal cream in India, which may affect its international market revenue, further depressing the stock price.

3. On July 28, analyst ratings showed Pfizer currently has a hold rating and is not listed among the top five recommended buy stocks, indicating weakened market confidence. The relative advantage of defensive sectors is expected to continue Stocks Ranked Among the Top by Market Capitalization in the Industry

Merck fell 0.83%. Based on recent news,

1. On July 29, Merck announced a dividend of $0.85 per share for the fourth quarter of 2026. This news had a short-term impact on the stock price, causing fluctuations.

2. In mid-July, Merck's oral PCSK9 inhibitor Lipfendra was approved by the U.S. FDA, becoming the first oral cholesterol medication taken once daily. The drug is priced at approximately $315 per month, and analysts expect peak annual sales to reach billions of dollars, helping the company diversify its product portfolio before the patent expiration of Keytruda.

3. On July 14, Hansoh Pharmaceutical reached a collaboration with Avere on HS-20118, with a transaction amount of up to $2.3 billion. This deal reflects a market reassessment of the value of oral cyclic peptide technology platforms, with multinational pharmaceutical companies like Merck having already established a presence in the oral cyclic peptide sector. Pharmaceutical stocks have recently shown strong overall performance